×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BIIB – biogen inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BIIB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/30
08:14 am
biib
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
1/28
09:07 am
biib
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus [Yahoo! Finance]
Low
Report
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus [Yahoo! Finance]
1/28
07:30 am
biib
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Low
Report
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
1/27
07:19 am
biib
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
1/25
06:42 pm
biib
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review [Yahoo! Finance]
Low
Report
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review [Yahoo! Finance]
1/25
06:30 pm
biib
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Low
Report
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/23
09:17 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $143.00 to $178.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $143.00 to $178.00. They now have a "neutral" rating on the stock.
1/21
04:37 pm
biib
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 [Yahoo! Finance]
Low
Report
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/14
06:00 am
biib
Form 8-K BIOGEN INC. For: Jan 13
Medium
Report
Form 8-K BIOGEN INC. For: Jan 13
12/3
04:43 pm
biib
Form 4 BIOGEN INC. For: Dec 01 Filed by: Viehbacher Christopher
Low
Report
Form 4 BIOGEN INC. For: Dec 01 Filed by: Viehbacher Christopher
11/13
08:28 pm
biib
Form SCHEDULE 13G/A BIOGEN INC. Filed by: PRIMECAP MANAGEMENT CO/CA/
Low
Report
Form SCHEDULE 13G/A BIOGEN INC. Filed by: PRIMECAP MANAGEMENT CO/CA/
11/10
08:15 am
biib
Form SCHEDULE 13G BIOGEN INC. Filed by: STATE STREET CORP
Low
Report
Form SCHEDULE 13G BIOGEN INC. Filed by: STATE STREET CORP
11/4
04:13 pm
biib
Form 4 BIOGEN INC. For: Oct 31 Filed by: Grogan Jane
Low
Report
Form 4 BIOGEN INC. For: Oct 31 Filed by: Grogan Jane
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/22
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
TOP News Decliners
10/22
Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch]
-11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: